Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Ellie Rashidghamat(King's College London), John A. McGrath(King's College London), Magdalena Martinez-Queipo(King's College London), Marcel van den Broek(St. Antonius Ziekenhuis), Anna E. Martinez(National Health Service), Chrysanthi Ainali(King's College London), Sophia Aristodemou(Guy's Hospital), Clarisse Maurin(Guy's and St Thomas' NHS Foundation Trust), John Mee(St Thomas' Hospital), Sonia Serrano, Alexandros Onoufriadis(Aristotle University of Thessaloniki), Venu Pullabhatla(National Health Service), Su M. Lwin(King's College London), Kasper Westinga(Utrecht University), Gabriela Petrof(Great Ormond Street Hospital), Francesco Dazzi(King's College London), Alka Saxena(Guy's and St Thomas' NHS Foundation Trust), Emanuele de Rinaldis(Target (United States)), Sabrina Zeddies(University Medical Center Utrecht), Alyson Guy(Guy's Hospital), Ineke Slaper‐Cortenbach(Maine Farmland Trust), Salma Ayis(King's College London), Duško Ilić(King's College London), Linda Ozoemena(Guy's Hospital), Jemima E. Mellerio(Great Ormond Street Hospital), Lu Liu(St Thomas' Hospital), James R. McMillan(Guy's Hospital), Tendai Kadiyirire(King's College London), Rashida Pramanik(Guy's and St Thomas' NHS Foundation Trust), Rosamund Nuamah(Guy's and St Thomas' NHS Foundation Trust)
Journal of the American Academy of Dermatology
November 28, 2019
Cited by 115


Related Papers